Close Menu

This article has been updated with additional information about coverage of NIPT.

NEW YORK – Natera has found that the performance of its Panorama noninvasive prenatal screening (NIPS) test has stayed consistently high over several years, even as testing has shifted to a younger age group with lower risk for fetal aneuploidies. In addition, the firm is nearing completion of a prospective clinical study that it says will further bolster these results, not only for common fetal trisomies but also for some microdeletions.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.